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the action potential. I
Na dysfunction can cause different types of arrhythmias. Several 
partners interact with the C-terminus of Nav1.5, including the Fibroblast Growth 
Factor Homologous Factor 1B (FHF1B), which modulates Nav1.5 inactivation. Its 
interaction site on Nav1.5 is still controversial, located either in the proximal or in the 
proximal and the distal parts of Nav1.5 C-terminus.
Here, we characterized two truncating mutations occurring in the last exon of 
SCN5A: R1860GfsX12 is a new mutation identifi ed in a patient with a mixed clinical 
picture of sick sinus syndrome and atrial fi brillation, and L1821fsX10 was previously 
reported, also with a complex clinical phenotype, and tested whether the distal region 
of the Nav1.5 C-terminus interacts with FHF1B.
Methods and Results: Western blot analysis of HEK cells transiently expressing 
each mutant channels showed their partial proteasomal degradation. However, both 
mutant channels reached the plasma membrane, as shown by cell surface biotinylation. 
Patch-clamp recordings showed a marked reduction in I
Na density, a -25mV shift of the 
steady-state inactivation, drastically slowed inactivation kinetics and a persistent I
Na 
when mutants were compared to wild type (WT). In cells co-expressing the WT and 
the R1860GfsX12 channels in a 1:1 ratio, the steady-state inactivation and inactivation 
kinetics were still altered. Co-immunoprecipitation studies showed that the interaction 
of both mutants with FHF1B was nearly abolished.
Conclusion: The loss of interaction of the mutants with FHF1B confi rms the 
involvement of the proximal and the distal parts of the Nav1.5 C-terminus in its 
interaction with FHF1B and is consistent with the shift of inactivation of I
Na. The mixed 
clinical picture of the patients is likely explained by the altered kinetics properties.
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Introduction: Inactivating mutations in SCN5A gene have been associated with 
Brugada syndrome. They are well recognized to generate a myocardial transmural 
electrical gradient that explains the pathophysiology of the pattern. Thus, Na channel 
blocker drug can reveal the ECG pattern. However, response to this test had never 
been described according to the presence of mutation in this gene. 
Methods: ECG parameters (P, PR, QRS, QT peak and QT end intervals; J wave 
amplitude in V1, V2, V3) of consecutive patients experimenting with a positive NA 
blocker challenge was double measured in 73 unrelated Brugada patients, blind to 
the genetic status. 
Results: 10 patients had known SCN5A mutation (14%) without any baseline 
clinical differences from those without SCN5A mutation. 
Baseline ECG reveal a lengthening of PR (181±27 vs 156±30; p=0.017) and QRS 
interval (101±15 vs 89±14; p=0.02). None other parameters were signifi cantly different.
During NA blocker test challenge, induction of Brugada pattern was not earlier 
in SCN5A mutation carriers. When ECG parameters were reach for Brugada pattern, 
ECG parameters were not signifi cantly different in the 2 groups.
No clinical difference was found after a mean follow up of 6 years.
Conclusion: SCN5A mutations in Brugada patients lead to a relative baseline 
lengthening of PR and QRS interval that disappears during NA blocker test. It 
suggests a non cumulative and a saturable effect of SCN5A in brugada syndrome’s 
pathophysiology.
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Many questions remain regarding both genetic and environmental modifi ers of 
arrhythmogenic right ventricular cardiomyopathy (ARVC).We report 3 families of 
ARVC in whom only mutation carriers with competitive sports activites had phenotypic 
expression of the disease. 
Three athletes (2 females, 14 and 53 yo; 1 male 26 yo) were resuscitated from 
sudden death during sports practice (>12 hours weekly).ARVC was diagnosed after 
resuscitation according to Task Force criterion.Genetic testing found mutations on PKP2. 
Genetic tests were performed in the families. Out of 31 individuals tested, PKP2 
mutation was identifi ed in 7. Evaluation of these families was performed including 
baseline ECG, Holter recording, exercise test, signal-averaged ECG, echocardiography 
and cardiac MRI. Mutation-carriers were 4 women, 3 men with a mean age of 48.9±28.9 
(range 17-80 yo). They all had less than 6 hours of weekly physical activity except 
one. Two of them (2 women, 74 and 80 yo) were treated for hypertension. They all had 
normal ECG. The patients with no sports activities had no evidence of late potentials, 
less than 200 PVC/day on Holter ECG recordings, no PVC on exercise tests and no 
right or left ventricle structural abnormalities. One asymptomatic mutation-carrier (17 
yo man) who had >8 hours sport practice/week (running, soccer) developed frequent 
PVC on Holter recordings, with echocardiographic and MRI abnormalities that met 
ARVC diagnosis criterion. 
In conclusion, in patients with PKP2 mutation, intense endurance sports practice for 
several years appears to be a strong determinant of ARVC phenotypic development and 
of malignant ventricular arrhythmias. On the contrary, a sedentary life was associated 
with the absence of development of ARVC in mutation carriers, suggesting a major 
role for physical activities in precipitating disease expression and that sports restriction 
may prevent its development in asymptomatic mutation carriers. 
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Introduction: The cardiac voltage-gated Na+ channel Nav1.5 underlies the 
cardiac Na+ current I
Na, which is essential for the generation and the transmission of 
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in patients affected by the Brugada Syndrome (BrS). We described the main clinical 
features of our included patients and the short term effect of HQ in this population.
Methods: QUIDAM is a double-blind randomized crossover study of two 1.5 
year periods (HQ versus placebo) in patients affected by the BrS and implanted with 
an ICD. BrS ECGs were submitted to an expert committee to confi rm the BrS type 
1 diagnosis. Patients with a confi rmed BrS were tested for HQ sensitivity during 
inclusion. An ECG was performed before and 3 hours after ingestion of HQ.
Results: Among the 77 patients fi les submitted to the scientifi c committee, 15 ECGs 
were not considered to be diagnostic for the BrS and 5 withdrew their consents before 
inclusion. PR interval 181±32 msvs 185±31 ms, QRS duration 104±18 msvs 105±20 
ms and ST-segment elevation 2±1 mm vs 2±2 mm were not signifi cantly modifi ed 
after HQ ingestion. On the contrary there was a signifi cant lengthening of the QTc 
interval, 403 ±29 msvs 415±31 ms (p-value<0.05) and a lengthening of the T(peak) 
– T(end) interval from 76.6±16.6 ms before HQ to 87.2±23.6 ms in V5 (p<0.001). 
One patient showed a 50 ms lengthening of the QTc interval and was then considered 
to be hypersensitive for HQ. No other signs of HQ intolerance were reported.
Conclusions: These results demonstrate that even in tertiary centers involved 
in the treatment of BrS patients, the diagnosis is diffi cult. We underlined also that 
HQ treatment did not changed the ST segment elevation and prolonged the T(peak) 
– T(end) duration in a short period.
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Introduction: QUIDAM is a French national multi-center prospective study, 
designed to evaluate the effi cacy of hydroquinidine (HQ) in decreasing arrhythmic events 
